Item 3.03. Material Modification to Rights of Security Holders.
On April 26, 2022, InVivo Therapeutics Holdings Corp. (the "Company") effected a
reverse stock split of the Company's common stock, par value $0.00001 per share
(the "Common Stock"), at a ratio of 1-for-25 (the "Reverse Split"). As a result
of the Reverse Split, every 25 shares of the issued and outstanding Common Stock
were automatically converted into one newly issued and outstanding share of
Common Stock, without any change in the par value per share. Any fractional
shares resulting from the Reverse Split have been rounded up to the nearest
whole share. In connection with the Reverse Split, the Company correspondingly
reduced the number of shares of authorized shares of Common Stock from
50,000,000 to 2,000,000. All outstanding stock options and warrants will be
adjusted as a result of the Reverse Split, as required by the terms of such
stock options and warrants.
As previously disclosed, the Board of Directors of the Company approved the
Reverse Split on April 14, 2022. On April 25, 2022, the Company filed a
Certificate of Change to effect the Reverse Split pursuant to Nevada Revised
Statutes Sections 78.207 and 78.209 with the Secretary of State of the State of
Nevada. Under Nevada law, the Company's Articles of Incorporation were deemed
amended at the effective time of the Reverse Split, 5:00 p.m. Eastern Time on
April 26, 2022.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
The information set forth in Item 3.03 of this Current Report on Form 8-K is
incorporated by reference into this Item 5.03. A copy of the Certificate of
Change is filed as Exhibit 3.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
3.1 Certificate of Change Pursuant to NRS 78.209, filed with the Nevada
Secretary of State, dated April 25, 2022.
104 The cover page of this Current Report on Form 8-K, formatted in Inline
XBRL.
© Edgar Online, source Glimpses